文献速递银屑病与炎症性皮肤病湿疹皮炎与荨麻疹自身免疫性与大疱性皮肤病

免疫介导炎症性疾病患者接种COVID-19疫苗的安全性与有效性综述

COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence.
PubMed 文献 · J Am Acad Dermatol · 2021-08-04

本文综述了免疫介导炎症性疾病(IMID)患者接种COVID-19疫苗的安全性和有效性证据及现有接种建议。现有证据表明,与健康对照相比,这些患者因接种疫苗而受到伤害的风险极小,通过接种避免重症COVID-19的获益超过理论风险。尚待解决的问题是使用生物制剂的患者能否产生足够的免疫应答,这可能取决于具体生物制剂和治疗指征,强调接种后随访的重要性。

要点

  • IMID患者接种COVID-19疫苗的伤害风险较健康对照无显著增加。
  • 多数患者接种获益(避免重症COVID-19)大于理论风险。
  • 使用生物制剂者的免疫应答是否充分尚不明确,需接种后随访。

核心结论

  • 现有证据表明IMID患者接种COVID-19疫苗的伤害风险较健康对照无显著增加,多数患者获益大于理论风险。
  • 使用生物制剂患者的免疫应答是否充分尚不明确,可能取决于具体生物制剂和治疗指征。

研究设计与样本

  • 本文为综述,汇总了关于IMID患者接种COVID-19疫苗安全性和有效性的现有证据及现有接种建议。

主要发现

  • 与健康对照相比,IMID患者因接种COVID-19疫苗受到伤害的风险极小。
  • 对多数患者而言,通过接种避免重症COVID-19的获益超过疫苗的理论风险。
  • 使用生物制剂的患者能否产生足够免疫应答尚不明确,可能取决于具体生物制剂和治疗指征。

临床怎么用

  • 皮肤科医生应熟悉IMID患者接种COVID-19疫苗的风险与获益,尤其是使用生物制剂者,以便与患者进行知情讨论。
  • 对接种疫苗的IMID患者进行随访,以确定疫苗在该人群中的安全性、有效性和持续时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dermatologists diagnose and treat many immune-mediated inflammatory diseases (IMID). Understanding the inherent immune dysregulation of these diseases as well as the additional disruption that comes as a result of IMID treatments has been important during the COVID-19 pandemic. With vaccines becoming widely available, dermatologists need to be familiar with the risks and benefits of vaccination in these patients, particularly those taking biologics, in order to have informed discussions with their patients. In this review, we present the current evidence related to COVID-19 vaccine safety and efficacy in patients with IMID and review existing recommendations for vaccination against SARS-CoV-2. Given the current evidence, there is minimal concern that these patients are at any greater risk of harm from COVID-19 vaccination compared to healthy controls. For most, the benefit of avoiding severe COVID-19 through vaccination will outweigh the theoretical risk of these vaccines. A question that is still outstanding is whether patients on biologics will generate a sufficient immune response to the vaccine, which may be dependent on the specific biologic therapy and indication being treated. This underscores the importance of following patients with IMID after vaccination to determine the safety, efficacy, and duration of the vaccine in this population.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Wack S, Patton T, Ferris LK, et al. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence. J Am Acad Dermatol. 2021. PMID: 34363909. doi:10.1016/j.jaad.2021.07.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。